AstraZeneca reported “surprise” Phase 3 wins for its investigational COPD antibody tozorakimab, showing success in two late-stage trials after mixed results earlier in development. The studies, Oberon and Titania, are expected to broaden use by enrolling patients across blood eosinophil counts and COPD severities, including current and former smokers. AstraZeneca did not release complete data in the announcement, saying results will be disclosed at an upcoming medical meeting. Still, the mechanism—blocking IL-33 signaling via a “reduced” form intended to limit interactions with another inflammatory molecule—differentiates the program from some IL-5/IL-4 axis approaches currently used in eosinophilic COPD. Analysts noted the potential to expand the eligible biologics population, positioning tozorakimab for a larger addressable market if efficacy and safety profiles hold in full data.